Inside Hawaiʻi’s Hemp Crackdown

In Waikīkī, the clearest evidence of Hawaiʻi’s hemp crackdown sits on retail shelving. Customers who once bought hemp-derived pre-rolls, vapes and edibles now encounter bare displays and a narrower selection. Honolulu Civil Beat documented the scene in August at Oʻahu Dispensary and Provisions, where one shopper described visiting several stores and leaving without the products he sought.

The empty shelves mark a decisive turn in a policy conflict that developed over five years. Hawaiʻi restricted smokable hemp flower and inhalable cannabinoid products in 2020. Retail sales continued in plain view as a national market for hemp-derived THC expanded under the 2018 Farm Bill. Businesses signed leases, hired workers and built supply chains around a market that federal law enabled and state enforcement rarely reached.

Act 269, adopted in 2025, gave the Hawaiʻi Department of Health a practical system for acting on those restrictions. Retailers entered a state registry, inspectors gained access to inventory, and agencies acquired clearer routes to embargo, seizure, fines and closure. Coordinated enforcement began July 1, 2026.

The resulting story concerns regulatory authority, commercial reliance and consumer access. It also offers a national case study in what happens when a state converts a long-standing prohibition into an active enforcement program after a retail market has matured around it.

A Market Built in the Enforcement Gap

Congress created the opening in 2018 by removing hemp from the federal definition of marijuana when the plant and its derivatives contain no more than 0.3% delta-9 THC by dry weight. Manufacturers soon used that framework to produce gummies, beverages, vapes, flower and pre-rolls containing intoxicating cannabinoids derived from hemp.

Hawaiʻi chose a narrower path. Act 14 of 2020 prohibited the sale of hemp leaf or floral material intended for smoking or inhalation and barred cannabinoid products designed for aerosol delivery. According to the Department of Health, those restrictions covered flower, pre-rolls, vapes and concentrates years before the 2026 crackdown.

Enforcement capacity lagged behind the statute. Mainland products continued arriving, local stores continued selling them and consumer demand grew. That gap produced two competing expectations. Regulators saw an expanding trade in products that Hawaiʻi law had restricted. Retailers saw years of open commerce, tax payments and supplier documentation as evidence of a durable business channel.

Act 269 supplied the missing enforcement architecture. The Legislature’s summary describes a registration mandate for manufactured hemp product retailers and distributors, inspection authority, seizure and forfeiture provisions, civil penalties and nuisance-abatement tools. Registration began Jan. 1, 2026, followed by a six-month grace period.

July 1 Changes the Street

On June 23, the Department of Health and the attorney general announced statewide enforcement beginning July 1. The notice directed retailers to remove prohibited inventory and listed a progression of consequences that included monetary penalties, embargo, seizure, destruction, civil injunctions and closure for persistent violations.

Alyas, the owner of four Oʻahu Dispensary and Provisions locations, said Department of Health officials visited two stores simultaneously, photographed products and identified merchandise that had to leave the shelves. He told High Times that agents warned of future fines, seizures and arrest. The initial visits concluded with warnings, according to Alyas, and his company removed the affected products.

The commercial impact followed immediately. Alyas estimates that the removals erased about 90% of company revenue and reduced the workforce by roughly a quarter. Civil Beat reported that 20 jobs remained at risk in August. These figures come from Alyas and describe the scale of his company’s dependence on the restricted categories.

Consumers experienced the policy as a sudden loss of access. Some sought inexpensive intoxicating products without entering Hawaiʻi’s medical cannabis program. Others, according to Alyas, used hemp products for sleep, pain, anxiety and personal wellness. The state’s compliance pathway now directs buyers toward permitted hemp products, Hawaiʻi’s medical dispensaries or abstention from the restricted categories.

Workers carried another share of the cost. A policy expressed through cannabinoid definitions translated into fewer shifts, smaller inventories and uncertain leases. The nuisance provisions in Act 269 also give landlords a direct reason to scrutinize tenants whose stores carry prohibited products.

The Economic Stakes

The crackdown reshapes a cannabis market with unusually tight entry controls. Hawaiʻi created its medical dispensary program in 2015 and capped the market at eight licenses. Licensees operate under testing, tracking, security and patient-access requirements that impose substantial costs. Hemp retailers operated through a separate channel with broader customer access and, in many cases, lower prices.

A 2025 market analysis commissioned by the Department of Health estimated total monthly cannabis spending in Hawaiʻi at $16.5 million to $32 million across medical, gray and illicit channels. Licensed medical dispensaries captured about $5.3 million per month. Among adult consumers outside the patient registry, the report estimated monthly spending on hemp-derived products at about $6.17 million, equal to roughly 30.9% of combined cannabis and hemp spending for that group.

The report’s authors flagged a limited sample of recent adult consumers and the absence of a question focused specifically on hemp-derived delta-9 THC. Even with those constraints, the estimate shows why hemp mattered to retailers, consumers and medical cannabis operators. It had become a material part of the state’s cannabinoid economy.

Patient enrollment was moving in the opposite direction. Civil Beat reported that Hawaiʻi’s medical cannabis registry declined from 34,125 people in December 2021 to 28,735 at the end of 2025, a 16% reduction. Licensed operators faced a contracting patient base while unlicensed retailers gained traffic from adults purchasing hemp-derived THC.

Regulators and medical operators frame the disparity around product testing, accountability and consumer protection. Retailers frame it around competition and access. Hawaiʻi’s enforcement program advances the first set of priorities and transfers commercial advantage toward the licensed medical channel. That redistribution is a practical consequence of the policy, regardless of the mixture of motives behind it.

Who Shaped the Rules

Public records provide context for how licensed-industry concerns reached lawmakers. Emails reviewed by Cannabis & Tech Today show that Noa Botanicals CEO Karlyn Laulusa communicated regularly with Rep. Scot Matayoshi, chair of the House Consumer Protection and Commerce Committee. In January 2025, Matayoshi’s office requested proposed language concerning delta-8 THC and related cannabinoids. Laulusa responded with a definition change and public-safety materials.

Later messages included maps of businesses Laulusa characterized as illegal operators, implementation discussions and requests for stronger hemp enforcement. In September 2025, she wrote that state-level laws could “protect the market” ahead of federal change. In January 2026, she described an unnamed Waikīkī retailer with four nearby locations as “the largest illegal dispensary.” Alyas says the passage referred to his company.

The correspondence documents sustained access and a clear economic interest in enforcement. Matayoshi told Civil Beat that consultation with regulated businesses forms part of legislative due diligence. Noa Botanicals, Aloha Green Apothecary and Cure Oʻahu supported the 2025 legislation, as did the Honolulu Police Department and the city prosecutor’s office.

The broader record shows a coalition built around enforcement, testing and the protection of the licensed system. It also shows that hemp retailers entered the debate after an incumbent industry had already developed close policy access. That imbalance matters because the final law placed market-changing authority inside the same department that regulates the eight medical licensees.

The Court Draws the Line

Alyas first sued the state in 2025. That action ended through a voluntary dismissal without prejudice in December, leaving the merits open for a new filing. Alyas and fellow retailer Kyler Falces-Cachola returned to federal court in January 2026 with claims involving federal preemption, interstate commerce, administrative authority and due process.

Their central theory held that the 2018 Farm Bill protected federally compliant hemp products from Hawaiʻi’s stricter retail restrictions. The state argued that Congress preserved broad state authority over hemp and that Hawaiʻi’s rules governed in-state sales without discriminating against mainland commerce.

On Sept. 4, U.S. District Judge Jill A. Otake dismissed the refiled case and denied leave to amend. As Bloomberg Law reported, the court concluded that federal hemp law leaves room for stricter state sales and distribution rules. The order gives Hawaiʻi a strong legal foundation for continued enforcement, subject to any appellate review.

The ruling answers the authority question at the district-court level. Policy design remains in the hands of lawmakers and regulators. Hawaiʻi can publish enforcement data, clarify product and testing standards, measure the effect on workers and consumers, and decide whether adult demand belongs in a medical program, a regulated adult-use channel or a tightly defined hemp market.

The state’s experience also carries a national lesson. A regulatory gap can harden into a market long before an agency is ready to police it. When enforcement finally arrives, legal compliance becomes an economic restructuring event. Hawaiʻi now has the authority and machinery to control hemp retail. The quality of the next phase will depend on transparency, proportionality and a clear destination for the consumer demand that remains.

Also Read

US Cannabis at a Crossroads

A national look at competing hemp definitions, consumer-safety proposals and the collision between agricultural, cannabinoid and cannabis policy.

Read the Article →